Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 2Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hematologic Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced Solid Malignancy, 1

Interventions

Rituximab 67Cyclophosphamide 52fludarabine phosphate 44Whole-Body Irradiation 36Mycophenolic Acid 33Peripheral Blood Stem Cell Transplantation 29Tacrolimus 27Busulfan 24Cyclosporine 21Antilymphocyte Serum 21Melphalan 18Filgrastim 16Etoposide 15Methotrexate 14Radiotherapy 12Lenalidomide 12Cord Blood Stem Cell Transplantation 12fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10Dexamethasone 9Bendamustine Hydrochloride 9Prednisone 8Bortezomib 8thymoglobulin 7idelalisib 7Flow Cytometry 7Calcium Dobesilate 7ibritumomab tiuxetan 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell, Marginal Zone × capivasertib × Clear all
NCT05008055 2024-12-20

CAPITAL

AstraZeneca

Phase 2 Completed
30 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡